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ABSTRACT 
Voltage gated Kv7.4 channels have been implicated in vascular smooth muscle cells 
(VSMCs) activity as they modulate basal arterial contractility, mediate responses to 
endogenous vasorelaxants, and are down-regulated in several arterial beds in different models 
of hypertension. Angiotensin II (Ang II) is a key player in hypertension that affects the 
expression of several classes of ion channels. In this study we evaluated the effects of Ang II 
on the expression and function of vascular Kv7.4. Western blot and quantitative PCR revealed 
that in whole rat mesenteric artery Ang II incubation for 1-7h decreased Kv7.4 protein 
expression without reducing transcript levels. Moreover, Ang II decreased XE991 (Kv7) –
sensitive currents, and attenuated membrane potential hyperpolarization and relaxation 
induced by the Kv7 activator ML213. Ang II also reduced Kv7.4 staining at the plasma 
membrane of VSMCs. Proteasome inhibition with MG132 prevented Ang II-induced 
decrease of Kv7.4 levels, and counteracted the functional impairment of ML213-induced 
relaxation in myography experiments. Proximity Ligation Assays showed that Ang II 
impaired the interaction of Kv7.4 with the molecular chaperone HSP90, enhanced the 
interaction of Kv7.4 with the E3 ubiquitin ligase CHIP, and increased Kv7.4 ubiquitination. 
Similar alterations were found in mesenteric VSMCs isolated from Ang II-infused mice. The 
effect of Ang II was emulated by 17-AAG that inhibits HSP90 interactions with client 
proteins. These results show that Ang II downregulates Kv7.4 by altering protein stability 
through a decrease of its interaction with HSP90. This leads to the recruitment of CHIP and 
Kv7.4 ubiquitination and degradation via the proteasome. 
Keywords: Angiotensin II/Heat shock protein/KCNQ/Kv7.4/Proteasome
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INTRODUCTION 
Hypertension is associated with increased arterial contractility and resistance to receptor-
mediated vasodilators. Kv7 channels (Kv7.1 – Kv7.5) are voltage-gated potassium (K
+
) 
channels encoded by KCNQ genes that regulate the contractile state of vascular smooth 
muscle at rest and contribute markedly to receptor-mediated vasorelaxations
1, 2
. Arterial 
smooth muscle cells express Kv7.1, Kv7.4 and Kv7.5, with negligible Kv7.2 and Kv7.3 levels
3
, 
and blockers of these channels such as XE991 or linopirdine can contract most arteries or 
enhance vasoconstrictor responses
4-6
. Conversely, agents that enhance Kv7 activity are 
effective vasorelaxants
4-7
. In addition, Kv7 blockers, as well as knockdown of Kv7.4 impairs 
vasorelaxations produced by receptor agonists in various arteries
2, 8, 9
. Notably, many 
receptor-mediated vasorelaxations are impaired in arteries from hypertensive animals, and 
any remaining relaxation is no longer sensitive to Kv7 blockade
8, 10
. The functional 
impairment is linked to a reduction of Kv7.4 protein abundance in renal, mesenteric and 
coronary arteries from hypertensive animals, which is not correlated with a reduction in gene 
transcript (KCNQ4), suggesting the involvement of post transcriptional mechanisms. Whilst 
some molecular determinants of the pathological changes in Kv7 channel expression 
occurring in the vasculature during hypertension have started to be unveiled
11
, the 
mechanisms that dictate the membrane abundance of Kv7.4 channels in smooth muscle are 
yet to be fully elucidated. K
+
 channel trafficking can be regulated by several processes, such 
as the protein internalization/endosomal recycling pathway
12
, and altered protein folding via 
changes in the interaction with molecular chaperones such as Heat Shock Proteins (HSPs)
13
. 
Here, we aim to uncover the processes governing the handling of Kv7.4 in vascular smooth 
muscle following treatment with Angiotensin II (Ang II), a molecule strongly associated with 
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cardiovascular dysfunction, to gain insight into the processes that control Kv7.4 membrane 
abundance during hypertension.  
METHODS   
Detailed methods are available in the Online Supplement (http://hyper.ahajournals.org). The 
authors declare that all supporting data are available within the article (and its online 
supplementary files). 
Animals 
All experiments were performed in accordance with the UK Animals (Scientific Procedures) 
Act (1986) and were approved by the local ethics committees (St George’s Animal Welfare 
Committee, Barts and The London School of Medicine, University of Reading Animal 
Welfare and Ethical Review Board). 10-12 weeks-old male Wistar rats (Charles River, U.K.) 
and C57BL/6J mice (12-18 weeks of age) were killed by cervical dislocation. Animals were 
housed in a climatically controlled environment, on a 12h light/dark cycle, with free access to 
water and standard food ad libitum.  
Statistical analysis 
All data are expressed as mean ± s.e.m. One- or two-way ANOVA test followed by a 
Dunnett’s or Tukey’s multiple comparisons test, and Student’s t-test (paired or unpaired) 
were used to determine statistical significance between groups, according to the different 
experiments. Differences were considered statistically significant when p<0.05.  
RESULTS 
Effects of Ang II on Kv7.4 levels and function 
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We first investigated the effects of Ang II on gross Kv7.4 levels in protein lysates from whole 
mesenteric arteries. Western blot experiments showed that 100nmol/L Ang II reduced Kv7.4 
protein levels by ∼50% after 1h compared to control vessels, by ~70% after 3h, and by 
∼80% after 7h treatment (Fig 1A). Incubation with Ang II did not reduce KCNQ4 mRNA 
levels even after 7h (Fig 1B), suggesting a post-transcriptional mechanism. Similar results 
were also observed in rat aorta (Fig S1A-B, http://hyper.ahajournals.org). To circumvent any 
possible non-specific binding of the Kv7.4 antibody we investigated the effects of Ang II 
treatment on a human smooth muscle cell line (SGVSM-9) transfected with EGFP-tagged 
Kv7.4, using an anti-GFP antibody. In SGVSM-9 cells transfected with EGFP-Kv7.4, in-cell 
western blot experiments showed that treatment for 1h with 100nmol/L Ang II induced a 
~20% decrease in EGFP-Kv7.4 with respect to control cells (Fig 1C). Moreover, in CHO cells 
expressing the angiotensin II receptor type 1 (AT1R) and EGFP-Kv7.4, incubation of 
100nmol/L Ang II for 1h decreased EGFP-Kv7.4 protein expression by ~30%, as measured 
by Western blot  (Fig S1C, http://hyper.ahajourn ls.org).  
We then evaluated the effects of Ang II on Kv7 function. Whole cell K
+
 currents were 
recorded from isolated mesenteric artery myocytes and the Kv7 current was identified as the 
component sensitive to the selective blocker XE991 (1µmol/L) (Fig S2A, 
http://hyper.ahajournals.org). Incubation of 100nmol/L Ang II for 3h decreased the amplitude 
of XE991-sensitive current by about 60% (Fig 1D). ML213 is an activator of Kv7.2, Kv7.4 
and Kv7.5 channels that has been characterized in several smooth muscles, including VSMCs 
from mesenteric arteries
14
. In sharp microelectrode studies on whole mesenteric arteries 
ML213 hyperpolarized the membrane potential by approximately 17mV; a subsequent 
application of the KATP channel activator levcromakalin (10µmol/L) further increased 
membrane resting potential (Fig 1E and Fig S2B, http://hyper.ahajournals.org, control). 
Treatment with Ang II for 2h blunted ML213-induced hyperpolarization (increase of 
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membrane potential by ~2mV) but did not affect the membrane hyperpolarization caused by 
levcromakalin (Fig 1E and Fig S2B, http://hyper.ahajournals.org, Ang II). ML213-induced 
relaxation of pre-contracted mesenteric arteries is abolished by the Kv7 blockers XE991 (Fig 
S3, http://hyper.ahajournals.org) and linopirdine
14
. Incubation of mesenteric arteries with 
Ang II impaired the relaxation of pre-contracted mesenteric arteries produced by ML213 (Fig 
1F and S2D, Fig S3, http://hyper.ahajournals.org), consistent with the loss of Kv7.4 function.  
Effects on Ang II on Kv7.4 subcellular distribution 
Kv7.4 subunits consistently show a clear and abundant peripheral distribution, following the 
shape of the cell membrane of the VSMC, whilst Kv7.1 was mainly intracellular and Kv7.5 
signal was altogether less apparent and only occasionally localized at the plasma membrane 
(Fig S3, http://hyper.ahajournals.org). The Kv7.4 staining overlapped with the signal of the 
plasma membrane marker wheat germ agglutinin in control conditions (WGA, Fig. 2A). 
Treatment with 100nmol/L Ang II (3h) reduced the membrane localization of Kv7.4 
concomitant with a decrease in the global level of Kv7.4 (Fig 2A). Fluorescence-intensity 
profiles along cross-sections f VSMCs showed that in control cells the Kv7.4 signal was 
higher in the membrane than cytosol (membrane:cytoplasm ratio 1.57±0.12), while in Ang II 
treated cells Kv7.4 fluorescence was similar between the two regions (membrane:cytoplasm 
ratio 0.88±0.10) (Fig 2B).  
Role of endosomal and proteasomal pathways in Ang II-mediated Kv7.4 degradation 
To gain insight about the cellular mechanisms that mediated the shift in Kv7.4 localization 
and reduction in total protein levels, mesenteric arteries were incubated with the endosome 
inhibitor dynasore or the proteasome inhibitor MG132 in presence or absence of Ang II. In 
Western blot experiments co-incubation of dynasore (DYN), used at concentrations 
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(100μmol/L) shown to be effective in previous studies15, did not fully prevent the reduction 
of Kv7.4 produced by 3h incubation with Ang II (Fig. 2C). Conversely, MG132 (20 µmol/L) 
fully prevented the Ang II-induced reduction of Kv7.4 (Fig. 2C). MG132 also counteracted 
the impairment of ML213-induced relaxation of mesenteric arteries by Ang II in myography 
experiments (Fig 2D).  
Role of oxidative stress in Ang II-induced Kv7.4 degradation 
Ang II is known to increase oxidative stress
16
 which induces proteasome-mediated protein 
degradation
17
. We therefore evaluated whether the observed increase of Kv7.4 protein 
degradation induced by Ang II was mediated by oxidative stress. In VSMCs, treatment with 
Ang II for 30min increased the production of reactive oxygen species (ROS) measured by the 
fluorescence dye ROS Deep Red (by ~50% compared to time-matched control), similarly to 
that caused by 1mmol/L H2O2 (increase by ~70%, Fig 3A). In contrast, longer incubation (3h) 
with Ang II did not significantly enhance ROS levels with respect to time-matched control, 
whereas H2O2 was still able to increase ROS levels (by ~40%, (Fig 3A). The ROS scavenger 
N-Acetyl-L-Cysteine (NAC, 1mmol/L) counteracted Ang II-induced ROS production (Fig 
S5, http://hyper.ahajournals.org), but did not prevent either Kv7.4 protein down-regulation 
(Fig 3B) or the impairment of ML213-induced relaxation in mesenteric arteries when co-
incubated with Ang II (Fig 3C).  
Role of HSPs in Ang II-mediated Kv7.4 degradation 
HSP70/90 machinery is abundantly expressed in eukaryotic cells, and is a key regulator of 
protein homeostasis in both physiologic and pathologic conditions
18
. Moreover, HSP70/90 
interact with Kv7.4 in heterologous-expression systems
19
. Neither HSP70 nor HSP90 
transcript/protein levels changed in Ang II-treated mesenteric arteries compared to control 
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vessels (Fig S6, http://hyper.ahajournals.org). Therefore, we investigated whether Ang II-
induced downregulation of Kv7.4 was mediated by an altered interaction with HSPs using 
Proximity Ligation Assay (PLA). No significant differences in the number of interactions 
between Kv7.4 and HSP70 were observed in isolated VSMCs treated with Ang II when 
compared to controls (Fig 4A). In contrast, a significant reduction (by ~40%) in Kv7.4:HSP90 
interactions was detected in VSMCs upon incubation with Ang II (Fig 4B). HSP70/90 
machinery is linked to the proteasome system via the co-chaperone and E3 ubiquitin-ligase 
CHIP (C-terminus of Hsp70-Interacting Protein). Incubation of VSMCs with Ang II 
enhanced the interaction of Kv7.4 with CHIP by ~30% (Fig 4C), and increased the number of 
ubiquitin molecules interacting with Kv7.4 by ~65% when compared to control (Fig 4D). 
These data suggested that Ang II reduced Kv7.4:HSP90 interactions thus enhancing protein 
ubiquitination via an increased interaction of Kv7.4:HSP70 complex with CHIP. To 
corroborate this, we studied the effect of 17-AAG (17-Demethoxy-17-(2-propenylamino) 
geldanamycin), a geldanamycin-analog which inhibits HSP90 function, on total Kv7.4 protein 
levels. Incubation of mesenteric arteries with 1µmol/L 17-AAG caused a reduction of Kv7.4 
protein by ∼60% (Fig 5A), increased the number of interactions between Kv7.4 and CHIP 
(Fig 5B), and the number of ubiquitin molecules interacting with Kv7.4 (Fig 5C).  
Role of HSPs-CHIP-ubiquitin system in Kv7.4 degradation in vivo 
Since Kv7.4 protein is down-regulated in Ang II-infused mice
7
, we investigated whether the 
observed alterations of HSPs-CHIP-ubiquitin system could be detected in the same in vivo 
model of prolonged exposure to Ang II. PLAs showed that the number of interactions of 
Kv7.4 with HSP70 in VSMCs isolated from mesenteric arteries of Ang II-infused mice was 
not significantly different from those isolated from saline-infused mice (Fig 6A), whereas a 
significant decrease in the number of Kv7.4:HSP90 interactions was observed in VSMCs 
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from Ang II- with respect to saline-infused mice (Fig 6B). Moreover, an increased interaction 
of Kv7.4 with CHIP (Fig 6C) and ubiquitin (Fig 6D) was detected in VSMCs from Ang II-
mice when compared to control groups.  
DISCUSSION 
Ang II reduces Kv7 expression and function via increased proteasome-mediated degradation 
In this study, we present novel and detailed mechanistic information showing how Ang II, a 
key mediator of the pathological changes occurring in vascular disease
16
, modulates Kv7.4 
channel expression, which is down-regulated in hypertension
7
. Ang II has been demonstrated 
to acutely (up to 25 min) suppress the XE991-sensitive Kv current in mesenteric VSMCs
20
, 
but no insight regarding the molecular mechanisms involved was provided, and the effects of 
longer exposure of Ang II on Kv7 expression and function were not studied. Our data show 
that treatment with Ang II (1-7h) reduced th  expression of Kv7.4 protein, decreased the 
amplitude of voltage-dependent currents sensitive to the pan-Kv7 channels blocker XE991 in 
VSMCs, blunted the hyperpolarization of the VSMCs membrane induced by the Kv7 
activator ML213, and impaired the vasorelaxant effects induced by the same drug in whole 
mesenteric arteries. In contrast, Ang II did not affect the ability of the KATP channel activator 
levcromakalin to hyperpolarize VSMCs. ML213 effects in smooth muscle are abolished by 
Kv7 blockers like XE991 (Fig S3, http://hyper.ahajournals.org) or linopirdine
14
, strongly 
suggesting the involvement of Kv7 channels in ML213-induced arterial relaxation. ML213 
has been reported to be more specific for channels formed by Kv7.2 (whose expression in 
VSMCs in negligible
3
) or Kv7.4 subunits
21
, but one study suggested that it also enhances the 
current mediated by Kv7.5
22
, which contributes with Kv7.4 to the formation of the mature 
channel in the vasculature
1, 23
. Due to the lack of Kv7 subunit-specific blockers, we could not 
rule out the involvement of Kv7.5 in ML213-induced relaxation. However, our 
Fo
r H
yp
ert
en
sio
n P
ee
r R
ev
iew
. D
o n
ot 
dis
trib
ute
.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
De
str
oy
 af
ter
 us
e.
9 
 
immunofluorescence data (Fig S4, http://hyper.ahajournals.org) together with previous 
evidence
2, 8, 9, 23
 infer that the reduction of vasorelaxant effects of ML213 prompted by Ang II 
was mediated by decreased Kv7.4 levels in VSMCs. Interestingly, ML213 still produced 
some relaxation in Ang II-treated arteries even though its ability to hyperpolarize was largely 
(but not entirely) lost by incubation with Ang II. A previous study revealed that 1µM ML213 
produced considerable relaxation of pre-contracted arteries without marked membrane 
hyperpolarization
14
. This apparent discrepancy in electro-mechanical coupling probably 
reflects the differences in experimental conditions, as isometric tension studies involved a 
pre-contracted and therefore depolarized artery compared to the microelectrode recordings 
performed on unstimulated arteries. Like other Kv7.2-7.5 activators ML213 works through 
stabilization of the open configuration that will be more apparent under depolarized 
conditions. However, further investigation regarding the role of Kv7 channels in regulating 
the electro-mechanical coupling in VSMCs is required.  
Kv7.4 down-regulation was also confirmed in clonal cells expressing heterologous Kv7.4 
channels, and was not accompanied by a reduction in mRNA levels, indicating that Ang II 
reduced Kv7.4 by post-transcriptional mechanisms. Modulation of protein trafficking, 
recycling and degradation has a considerable impact on K
+ 
channels expression and 
function
24
 and dysregulation of recycling/degradation pathways has been linked to 
channelopathies such as hereditary arrhythmias or cystic fibrosis
24
. Our findings reveal that 
degradation of Kv7.4 protein by Ang II treatment and the subsequent functional impairment 
of Kv7-dependant vasorelaxation was prevented by proteasome inhibition. Ang II has been 
shown to induce proteasome degradation of large conductance calcium activated BK 
channels via increased endosome-mediated internalization in VSMCs, and Kv11.1 (ERG) 
channels in over-expression systems
15, 25
. Interestingly, in contrast to the above studies where 
Ang II effects were noticeable after prolonged treatment (7-24h), we observed 
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downregulation and altered subcellular distribution of Kv7.4 after as little as 1h. Moreover, 
the lack of effect of dynasore in fully restoring Kv7.4 protein levels suggest that the 
endosomal pathway does not play a primary role in Ang II-induced Kv7.4 down-regulation in 
contrast to BKCa channels
15
. Previous studies have established that Ang II causes oxidative 
stress in target cells
16
, and that the increased ROS levels activate the ubiquitin-proteasome 
system, as a protective mechanism to prevent the accumulation/aggregation of oxidized 
proteins
17
. In our experiments, Ang II caused a rapid increase in ROS levels (30min) which 
did not persist with longer exposure (3h), and the ROS scavenger N-Acetyl-L-Cysteine did 
not prevent the down-regulation of Kv7.4 levels and function prompte  by Ang II. Although 
we cannot exclude the possibility that sustained oxidative stress reduces Kv7.4 levels, our 
data suggest that the early burst of ROS production induced by Ang II was not sufficient to 
alter Kv7.4 abundance, and that the activation of the proteasome system triggered by 
oxidative stress was not the main mechanisms involved in Ang II-induced downregulation of 
Kv7.4.  
Ang II-induced decrease of Kv7.4:HSP90 interaction promotes the ubiquitination of Kv7.4 
Ang II affects protein folding in hypertensive mice
26
, regulates the activity of HSPs, which 
mediate some maladaptive responses occurring in hypertension
27
, and also regulate ion 
channel folding. HSP90 in particular, plays a pivotal role in the folding of the cystic fibrosis 
transmembrane conductance regulator (CFTR), the ClC-2 chloride channel
28
, HERG 
channel
13
 and the KATP potassium channel
29
. Moreover, enhancement of the HERG:HSP90 
interaction is responsible for the increased membrane trafficking induced by estradiol
30
. 
Reduced binding of HSP90 decreases the interaction of client proteins with the HSP40-
HSP70-HOP chaperone pathway that promotes forward trafficking, and increases interaction 
with HSP70-ubiquitin ligase CHIP complexes, which lead to proteasome-mediated 
degradation
31
. Our data reveal that the molecular chaperones HSP70/90 interact with Kv7.4 in 
Fo
r H
yp
ert
en
sio
n P
ee
r R
ev
iew
. D
o n
ot 
dis
trib
ute
.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
De
str
oy
 af
ter
 us
e.
11 
 
native VSMCs, and that Ang II treatment selectively reduced the interaction of Kv7.4 with 
HSP90 in this physiological environment. In heterologous expression systems, modulating 
HSP90 isoforms levels either by overexpression or silencing strategies revealed a differential 
role in Kv7.4 maturation of the two major HSP90 isoforms, namely α and β, with β-isoform 
promoting protein folding, and α-isoform enhancing CHIP-mediated proteasomal 
degradation
32
. Although some distinctive features exist, HSP90 isoforms exert similar 
actions, with many functions being characteristic of both isoforms and only associated more 
frequently to one of them
33
. Moreover, their expression is differentially regulated, with a 
constitutive form (HSP90β) and an inducible one (HSP90α). Although we did not investigate 
the contribution of α- or β-isoform, in our experiments we did not observe any change in 
HSP90 levels, suggesting that HSP90 expression was not modified by Ang II incubation, and 
that a different mechanism was responsible for the alteration in Kv7.4:HSP90 binding. 
Covalent modifications, including phosphorylation, acetylation and nitrosylation, influence 
the activity of HSP90 and consequently the maturation of selected clients. Phosphorylation 
and acetylation slow down HSP90 activity, resulting in a reduced maturation of client 
proteins
34, 35
. Therefore, Ang II might activate different pathways ultimately altering HSP90 
and/or Kv7.4, modifying their ability to interact. Irrespective of the molecular mechanism, the 
ultimate effect was an increased interaction of Kv7.4 with CHIP and an enhanced 
ubiquitination of Kv7.4 as determined by PLA. This hypothesis was corroborated by studies 
with 17-AAG, a pharmacological inhibitor of HSP90, that in our experiments reproduced the 
effects of Ang II in terms of Kv7.4 down-regulation, interaction with CHIP and 
ubiquitination. Our results are in line with previous evidence showing that pharmacological 
inhibition of HSP90 induces rapid degradation of client proteins through the ubiquitin-
proteasome pathway
13, 36
.  
PERSPECTIVES 
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We show for the first time in vascular smooth muscle that Ang II enhances Kv7.4 degradation 
via the ubiquitin-proteasome system, through a reduced interaction with HSP90. The specific 
pathway(s) activated by Ang II, as well as the possible molecular modifications occurring in 
all the interactors (including additional co-chaperones) will need to be further investigated. 
Indeed, Ang II can activate diverse intracellular pathways, including non G-protein signaling, 
and modulate several processes, such as inflammation
16
, which might in turn regulate HSPs 
activity and therefore protein stability and degradation. However, the present study has 
identified a novel and dynamic regulation of Kv7.4 that impacts considerably on vascular 
physiology.  Noticeably, we showed that these alterations also occur in vivo after chronic 
exposure to Ang II, a well-known model of hypertension where Kv7.4 expression and 
function is reduced
7
, suggesting that the observed reduction of Kv7.4 protein stability and 
enhanced degradation play a role also in the pathological changes occurring in hypertension. 
Since modulators of HSP90 function are being developed therapeutically
37-39
, these data 
provide a possible new therapeutic strategy for the treatment of hypertension. 
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NOVELTY AND SIGNIFICANCE 
What is new. We showed that Ang II decreases the expression and function of Kv7.4 
potassium channels in vascular smooth muscle cells by reducing its interaction with 
chaperone protein HSP90 and altering protein stability.  
What is relevant. Kv7.4 is an important mediator of arterial relaxation and is down-
regulated in hypertension, a condition where Ang II is dysregulated. Increasing HSP90 
activity might represent a new strategy to treat hypertension.        
Summary. Ang II down-regulates Kv7.4 by disrupting its interaction with HSP90, which 
lead to the recruitment of the ubiquitin-ligase CHIP and the subsequent protein degradation 
via the proteasome.
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FIGURE LEGENDS 
Fig. 1. Effects of Ang II on Kv7.4 expression and function. (A) Top: representative western 
blot showing Kv7.4 (detected with an anti-Kv7.4 antibody) and β-actin in mesenteric arteries 
after incubation with 100nmol/L Ang II for 1, 3 or 7 hours. Bottom: Quantification of 
western blot experiments. n=4-6. *=p<0.05: **=p<0.01 (Student’s t-test). (B) Quantitative 
PCR showing kcnq4 mRNA levels after incubation with 100nmol/L Ang II for 7h. Data are 
expressed using the 2
-ΔCt
 formula. (C) In cell western blot showing the levels of EGFP-Kv7.4 
(detected with an anti-GFP antibody) in transfected SGVSM-9 after incubation with 
100nmol/L Ang II for 1h. Data are expressed as percentage of the average of the controls for 
each experimental session. n=12-14 wells per experimental point from 3-4 sessions. 
***=p<0.001 (Student’s t-test). The inset shows a SGVSM9 cell transfected with EGFP-
Kv7.4, with GFP fluorescence (green pseudocolor) and DAPI staining (blue pseudocolor), 
proving the effective expression of EGFP-Kv7.4 protein. Scale bar: 5µm. (D) Mean current-
voltage relationship (I-V) of the XE991-sensitive current in mesenteric VSMCs after 3 hours 
incubation in absence (control, black) or in presence (Ang II, grey) of 100nmol/L Ang II. n=5 
cells per experimental point from 5 rats. **=p<0.01: ****=p<0.0001 (two-way ANOVA). 
(E) Changes in resting membrane potential (ΔEm) of VSMCs in whole mesenteric artery 
induced by 10µmol/L ML213 (black columns) and 10µmol/L levcromakalim (grey columns) 
after 2 hours incubation in absence (control) or in presence (Ang II) of 100nmol/L. (F) 
Isometric tension recordings in mesenteric arteries incubated for 3 hours in absence (CTL, 
black) or presence (Ang II, grey) of 100nmol/L Ang II. The graph shows the relaxation 
induced by increasing concentration of ML213 in arteries pre-contracted with 1μmol/L 
U46619. Data are expressed as percentage of the maximum contraction to U46619. n=4-5. 
**=p<0.01; ***=p<0.001 (two-way ANOVA). 
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Fig. 2. Effects of Ang II on Kv7.4 subcellular distribution in mesenteric artery myocytes 
and role of endocytosis and proteasome in Ang II-induced down-regulation of Kv7.4. (A) 
Immunofluorescence experiments showing Kv7.4 (red pseudocolor) in absence (CTL) or in 
presence (Ang II) of 100nmol/L Ang II. Staining of the plasma membrane marker wheat 
germ agglutinin (WGA, green pseudocolor) and nuclear marker DAPI (blue presudocolor) 
are also shown. Scale bar: 5µm. (B) Top: fluorescence intensity profiles for Kv7.4 (red) and 
WGA (green) along the yellow line drawn in the pictures, expressed as Arbitrary Units (AU), 
in control (CTL) or Ang II-treated VSMCs. Regions where WGA intensity was <5AU were 
considered as cytosol (C), while portions where intensity was above the threshold were 
identified as plasma membrane (M). Bottom: bar graph showing the ratio between the 
average fluorescence intensities in the plasma-membrane and cytosol in VSMCs. For each 
cell, the mean of the ratios obtained along three random lines was calculated. n=15 cells per 
experimental point, obtained from 3-4 rats in 3-4 sessions. ***=p<0.001 (Student’s t-test). 
(C) Top: representative western blot showing Kv7.4 and β-actin proteins in mesenteric 
arteries after incubation for 3h with different combinations of 100nmol/L Ang II, 100μmol/L 
dynasore (DYN), and 20μmol/L MG132, as indicated. Bottom: quantification of western blot 
experiments. Normalized Kv7.4 intensities are expressed as percentage of control. n=6: 
**=p<0.01, ns=non significant (one-way ANOVA). (D) Isometric tension recordings in 
mesenteric arteries incubated for 3 hours in control conditions or with 100nmol/L Ang II in 
absence of presence of 20μmol/L MG132. The graph shows the relaxation to ML213 in 
arteries pre-contracted with 300nmol/L U46619. Data are expressed as percentage of the 
maximum contraction to U46619. n=4-6. *=p<0.05: **=p<0.01: ****=p<0.0001 (two-way 
ANOVA). 
Fig. 3. Role of oxidative stress in the downregulation of Kv7.4 induced by Ang II. (A) 
Left: representative images showing the fluorescence of the ROS-sensitive dye ROS Deep 
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Red in mesenteric VSMCs after incubation for 30 min (upper panels) or 3 hours (lower 
panels) in control medium (CTL) or in presence of 100nmol/L Ang II or 1mmol/L H2O2. 
Right: quantification of ROS Deep Red fluorescence intensity in VSMCs, expressed as 
Arbitrary Units (AU). n=35-48 cells obtained from 4-5 rats per experimental point in 4-5 
sessions. *=p<0.05, ns=not significant (one-way ANOVA). (B) The inset shows a 
representative western blot of Kv7.4 and β-actin proteins in mesenteric arteries after 
incubation for 3 hours with different combination of 100nmol/L Ang II and 1mmol/L of N-
Acetyl-L-Cysteine (NAC), as indicated. The bar graph shows the quantification of western 
blot experiments. n=6. *=p<0.05 (one-way ANOVA). (C) Isometric tension recordings in 
mesenteric arteries incubated for 3 hours in control condition or with 100nmol/L Ang II in 
absence of presence of 1mmol/L NAC. The graph shows the relaxation to ML213 in arteries 
pre-contracted with 1μmol/L U46619. Data are expressed as percentage of the maximum 
contraction to U46619. n=6. **=p<0.01, ***=p<0.001 ****=p<0.0001 (two-way ANOVA). 
Fig. 4. Effects of Ang II on Kv7.4 int raction with Heat Shock Proteins and ubiquitin. 
Proximity Ligation Assay showing the interaction of Kv7.4 with HSP70 (A), HSP90 (B), 
CHIP (C), and ubiquitin (D) in mesenteric artery myocytes. Representative fluorescence and 
bright field (insets) confocal mid-cell xy sections of mesenteric VSMCs in absence (CTL) or 
presence (Ang II) of 100nmol/L Ang II are shown for each panel. Red puncta indicate target 
proteins are in close proximity (<40 nm). Bar graphs show the quantification of the mean 
number of PLA signals per mid-cell xy section. n=17-40 cells from 3-4 rats per experimental 
point in 3-4 sessions. *=p<0.05, ***=p<0.001, ****=p<0.0001 (Student’s t-test). Nuclei 
(DAPI staining, blue) are also shown. Scale bar: 5µm.  
Fig. 5. Effects of HSP90 inhibition on Kv7.4 levels, interaction with CHIP, and 
ubiquitination. (A) Left: representative western blot showing Kv7.4 and β-actin in 
mesenteric arteries incubated with DMSO (CTL) or 1μmol/L 17-AAG. Right: quantification 
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of western blot experiments. n=5. *=p<0.05 (Student’s t-test). (B-C) Proximity Ligation 
Assay showing the interaction of Kv7.4 with CHIP (B) and ubiquitin (C) in mesenteric artery 
myocytes. Representative fluorescence and bright field (insets) confocal mid-cell xy sections 
of mesenteric artery myocytes incubated with DMSO (CTL) or 1μmol/L 17-AAG are shown 
for both panels. Red puncta indicate target proteins are in close proximity (<40nm). Nuclei 
(DAPI staining) are shown in blue pseudocolor. Scale bar: 5µm. Bar graphs show the 
quantification of the mean number of PLA signals per mid-cell xy section. n=24-44 cells 
from 3-4 rats per experimental point in 3-4 sessions. *=p<0.05, ****=p<0.0001 (Student’s t-
test). 
Fig. 6. Kv7.4 interaction with Heat Shock Proteins, CHIP and ubiquitin in Ang II-
infused mice. Proximity Ligation Assay showing the interaction of Kv7.4 with HSP70 (A), 
HSP90 (B), CHIP (C), and ubiquitin (D) in mesenteric artery myocytes obtained from mice 
infused for 28 days with saline solution or Ang II. Representative fluorescence and bright 
field (insets) confocal mid-cell xy sections of mesenteric VSMCs from saline- or Ang II- 
infused mice are shown for each panel. Red puncta indicate target proteins are in close 
proximity (<40 nm). Bar graphs show the quantification of the mean number of PLA signals 
per mid-cell xy section. n=35-40 cells from 4 mice per experimental group. *=p<0.05, 
**=p<0.01, ****=p<0.0001 (Student’s t-test). Nuclei (DAPI staining, blue) are also shown. 
Scale bar: 5µm.  
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